RESUMEN
The actions of individual corticotropin-releasing hormone (CRH) receptor (CRHR1 and CRHR2) were studied on the hyperthermia caused by urocortin 1, urocortin 2 and urocortin 3 in rats. Urocortin 1, urocortin 2 or urocortin 3 was injected into the lateral brain ventricle in conscious rats and the colon temperature was measured at different times following injection, up to 6h. In order to study the possible role of CRH receptors, the animals were treated with a urocortins together with the urocortin receptor inhibitors CRF 9-41, antalarmin and astressin 2B to influence the action of urocortins in initiating hyperthermia. Urocortin 1 at a dose of 2microg caused an increase in colon temperature, maximal action being observed in body temperature at 3h. CRH 9-41 and antalarmin, CRHR1 receptor antagonists, prevented the urocortin-induced increase in colon temperature while astressin 2B (CRHR2 receptor antagonist) was ineffective. Urocortin 2 at a dose of 2microg showed a byphasic action in increase in colon temperature having the first peak between 30 min and 1h and the second peak at 4h following treatment. CRF (9-41) and antalarmin was ineffective while astressin 2B fully blocked the action of urocortin 2. Urocortin 3 in a dose of lmicrog increased colon temperature; the maximal effect was observed at 2h. CRF (9-41) and antalarmin was ineffective while astressin 2B fully blocked the action of urocortin 3. The results demonstrated that urocortin 1, 2 or 3 when injected into the lateral brain ventricle caused increases in body temperature is mediated by urocortin receptors. The action of urocortin 1 is mediated by CRHR1 receptor, while in the action of urocortin 2 and urocortin 3 CRHR2 receptor is involved.
Asunto(s)
Hipertermia Inducida , Receptores de Hormona Liberadora de Corticotropina/fisiología , Urocortinas/farmacología , Animales , Temperatura Corporal/efectos de los fármacos , Colon/efectos de los fármacos , Hormona Liberadora de Corticotropina/farmacología , Inyecciones Intraventriculares , Masculino , Fragmentos de Péptidos/farmacología , Péptidos Cíclicos/farmacología , Pirimidinas/farmacología , Pirroles/farmacología , Ratas , Ratas WistarRESUMEN
The actions of individual urocortins on colon temperature were studied in rats. Urocortin 1, urocortin 2 or urocortin 3 was injected into the lateral brain ventricle in conscious rats and the colon temperature was measured at different times following injection, for up to 6 h. In order to study the possible role of prostaglandins, the animals were treated with either a urocortin together with the pyrazolone derivative noraminophenazone to inhibit the action of cyclooxygenase in initiating hyperthermia, or with noraminophenazone 30 min following urocortin administration to act on existing hyperthermia. Noraminophenazone was administered intramuscularly in a dose of 50 mg/kg. Urocortin 1 caused a dose-related increase in colon temperature, maximal action being observed at a dose of 2 microg with the maximal increase in body temperature at 4 h. Noraminophenazone prevented the urocortin-induced increase in colon temperature and attenuated the already existing elevated body temperature. Somewhat similar action was observed with urocortin 2. However, following treatment with 0.5 or 1.0 microg urocortin 2, the action was already over at 2 h, whereas 2 microg increased the colon temperature steadily, with a maximum at 4 h. Noraminophenazone blocked or diminished the action of urocortin 2. Urocortin 3 in a dose of 1 microg was the most effective in increasing the colon temperature; the maximal effect was observed at 2 h. Noraminophenazone blocked the development of urocortin 3-induced hyperthermia, or attenuated it when the hyperthermia was already present. The results demonstrated that urocortin 1, 2 or 3 caused increases in body temperature when injected into the lateral brain ventricle, though the optimal dose and the duration of hyperthermia differed for the individual urocortins. The cyclooxygenase inhibitor blocked or diminished the action of these urocortins, indicating the involvement of prostaglandins in urocortin-induced hyperthermia.
Asunto(s)
Temperatura Corporal/efectos de los fármacos , Hormona Liberadora de Corticotropina/farmacología , Animales , Antipirina/análogos & derivados , Antipirina/farmacología , Ventrículos Cerebrales/citología , Ventrículos Cerebrales/efectos de los fármacos , Ventrículos Cerebrales/metabolismo , Colon/citología , Colon/fisiología , Inhibidores de la Ciclooxigenasa/farmacología , Fiebre/inducido químicamente , Masculino , Prostaglandinas/metabolismo , Prostaglandinas/farmacología , Ratas , Ratas Wistar , Factores de Tiempo , UrocortinasRESUMEN
The action of urocortin on one-way passive avoidance learning was tested in mice. Urocortin was administered into the lateral brain ventricle and the latency of the passive avoidance response was measured 24 h later. For study of the roles of various neurotransmitters in mediating the action of urocortin on the consolidation of memory, the animals were pretreated with different receptor antagonists. Urocortin facilitated the acquisition, consolidation and also retrieval of the passive avoidance response. The following receptor antagonists blocked the action of urocortin on consolidation: haloperidol, atropine, phenoxybenzamine, bicuculline, the CRF antagonist CRF9-41 and methysergide. Propranolol attenuated, but did not fully block the action of urocortin, while naloxone and nitro-L-arginine were ineffective. The results obtained demonstrate that urocortin is able to improve learning and memory and also retrieval processes in a passive avoidance learning in mice. D2, muscarinic cholinergic, alfa-adrenergic, CRF, serotonergic (5HT 1-2), GABA B receptors are involved in the consolidation of the passive avoidance response.
Asunto(s)
Reacción de Prevención/efectos de los fármacos , Hormona Liberadora de Corticotropina/farmacología , Neurotransmisores/metabolismo , Antagonistas Adrenérgicos alfa/farmacología , Antagonistas Adrenérgicos beta/farmacología , Análisis de Varianza , Animales , Atropina/farmacología , Reacción de Prevención/fisiología , Conducta Animal , Bicuculina/farmacología , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Antagonistas del GABA/farmacología , Antagonistas de Hormonas/farmacología , Masculino , Metisergida/farmacología , Ratones , Antagonistas Muscarínicos/farmacología , Fragmentos de Péptidos/farmacología , Fenoxibenzamina/farmacología , Propranolol/farmacología , Tiempo de Reacción/efectos de los fármacos , Antagonistas de la Serotonina/farmacología , UrocortinasRESUMEN
The action of PACAP-38 was studied by measuring the anxiogenic-anxiolytic behavior of rats in an elevated plus maze. PACAP-38 was administered into the lateral brain ventricle and the behavior of the animals was measured 3h later. The possible involvement of transmitters was measured by pretreating the animals with receptor blockers which alone did not influence the task, but in the doses used were effective with other neuropeptides. The receptor antagonist PACAP 6-38 (a PAC 1/VPAC2 receptor antagonist of PACAP-38 receptor), haloperidol (a non-selective dopamine receptor antagonist), phenoxybenzamine (an α1/α2ß-adrenergic receptor antagonist), propranolol(a ß-adrenergic receptor antagonist), bicuculline (a gamma-aminobutyric acid subunit A receptor antagonist), methysergide (a nonselective 5-HT2 serotonergic receptor antagonist), atropine (a nonselective muscarinic acetylcholine receptor antagonist), naloxone (a nonselective opioid receptor antagonist) and nitro-l-arginine which acts by blocking the enzyme nitric oxide synthase, thereby blocking the nitric oxide synthesis, were tested. The following parameters were measured: the time spent in open arms/the time spent in total entries. PACAP-38 decreased the ratio of time spent in open arms to the time spent in total entries, indicating anxiogenic action. The total number of entries was not altered significantly either by PACAP-38 or by the receptor blockers. The following receptor blockers diminished the action of PACAP-38: PACAP 6-38,haloperidol, methysergide, naloxone and nitro-l-arginine. Pretreatment with atropine, phenoxybenzamine, propranolol and bicuculline did not influence the action of PACAP-38 on the time spent in open arms. The results demonstrate that PACAP-38 administered into the lateral brain ventricle exerted anxiogenic action at 3 h following treatment. Pretreatment of the animals with various receptor blockers indicated that a nonselective dopaminergic receptor antagonist, 5HT2 serotonergic and opioid receptors, nitric oxide and PAC1 receptors are involved in the anxiogenic action induced by PACAP-38.
Asunto(s)
Ansiedad/tratamiento farmacológico , Ansiedad/metabolismo , Neurotransmisores/metabolismo , Neurotransmisores/farmacología , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa/farmacología , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria/metabolismo , Antagonistas Adrenérgicos/farmacología , Antagonistas Adrenérgicos beta/farmacología , Animales , Arginina/análogos & derivados , Arginina/farmacología , Atropina/farmacología , Bicuculina/farmacología , Antagonistas de Dopamina/farmacología , Conducta Exploratoria/efectos de los fármacos , Haloperidol/farmacología , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Metisergida/farmacología , Antagonistas Muscarínicos/farmacología , Naloxona/farmacología , Antagonistas de Narcóticos/farmacología , Compuestos Nitrosos/farmacología , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/farmacología , Fenoxibenzamina/farmacología , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa/metabolismo , Propranolol/farmacología , Ratas , Ratas Wistar , Receptores de GABA/efectos de los fármacos , Receptores de GABA/metabolismo , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria/agonistas , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria/antagonistas & inhibidores , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria/clasificación , Antagonistas del Receptor de Serotonina 5-HT2/farmacologíaRESUMEN
This review summarizes the action of atrial natriuretic (ANP) and some related compounds such as BNP, CNP and fragments on the central nervous system, based mainly on the results obtained in the author's laboratory. The aim of the investigations was to assess the physiological significance of the natriuretic peptide family in the brain by administering the peptides into the lateral brain ventricle. Effects were studied on motivated behavior, including active and passive avoidance learning, food-reinforced conditioning, open-field activity, electroshock-induced amnesia, development of morphine tolerance and dependence, and picrotoxin-kindled seizure syndrome. Antisera against ANP were used in order to follow the specificity of the resulting action. The role of neurotransmitters in the mediation of peptide action was elucidated by treating the animals with receptor blockers before peptide administration.
Asunto(s)
Factor Natriurético Atrial/farmacología , Conducta Animal/efectos de los fármacos , Motivación , Proteínas del Tejido Nervioso/farmacología , Neuropéptidos/farmacología , Secuencia de Aminoácidos , Animales , Datos de Secuencia Molecular , Péptido Natriurético Encefálico , RatasRESUMEN
The role of nitric oxide on passive avoidance learning was studied by administering L-arginine or D-arginine to male rats in a passive avoidance paradigm. L-Arginine administered into the lateral brain ventricle at a dose of 1.25 microg showed a tendency to increase the passive avoidance latency, and 2.5 microg exerted almost maximal action, but the action gradually increased still further up to 20 microg tested. D-Arginine had no action. Peripheral administration (intraperitoneal) of L-arginine facilitated the consolidation of passive avoidance learning in a dose-dependent manner. A significant increase in passive avoidance response was obtained following an injection of 100 mg/kg L-arginine. When L-arginine was given i.c.v. with a selected dose of 5 microg, 30 min prior to a learning trial, the latency of the passive avoidance response was likewise lengthened. However, when L-arginine was given 30 min before the 24-hr testing (retrieval), it was ineffective. It was also ineffective when given 6 hr after the training trial. However, when L-arginine was administered immediately following the training trial, the action in improving the consolidation could be detected 6 hr after the training trial. Nitro-L-arginine, which blocks nitric oxide synthase, can also block the facilitation of consolidation caused by the nitric oxide donor L-arginine. The nitric oxide synthase inhibitor per se in different doses had no action on the learning of a passive avoidance task. The results indicate that nitric oxide is able to facilitate the learning and consolidation of memory in a passive avoidance paradigm, but it is ineffective in retrieval processes. The results also suggest that, under the experimental circumstances used, nitric oxide is involved only in the facilitated learning and memory processes caused by pharmacological effect of L-arginine, and not involved in normal learning processes.
Asunto(s)
Reacción de Prevención/fisiología , Óxido Nítrico/fisiología , Animales , Conducta Animal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Técnicas In Vitro , Inyecciones Intraventriculares , Masculino , Óxido Nítrico Sintasa/antagonistas & inhibidores , Nitroarginina/farmacología , Ratas , Ratas WistarRESUMEN
The effects of somatostatin, administered into different areas of the brain were studied in preliminary picrotoxin-kindled rats. The injection of somatostatin into the lateral ventrical of the brain (i.c.v.) (1.8 nmol), the hippocampus (0.6 nmol) or the amygdala (0.6 nmol), resulted in a decrease in the severity of the picrotoxin-induced convulsions. Application of the peptide into the caudate-putamen or the substantia nigra reticulata did not alter the behavioural manifestations of the kindled seizures. The local injection of anti-somatostatin serum (1:5) into the hippocampus increased the severity of the kindled convulsions and blocked the anticonvulsive effect of somatostatin, given intraventricularly. Local administration of anti-somatostatin serum into the amygdala did not alter the kindled seizures and did not abolish the anticonvulsive action of somatostatin given intraventricularly. It is concluded that somatostatin could take part in endogenous control of seizures through a suppressant influence on limbic structures; the hippocampus could be a specific site for the antiepileptic action of somatostatin.
Asunto(s)
Picrotoxina , Convulsiones/inducido químicamente , Somatostatina/farmacología , Animales , Inyecciones Intraventriculares , Excitación Neurológica/efectos de los fármacos , Masculino , Ratas , Ratas Endogámicas , Convulsiones/prevención & control , Somatostatina/administración & dosificación , Somatostatina/inmunologíaRESUMEN
The possible cataleptogenic or anticataleptic effects of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and desulphated CCK-8 (CCK-8-NS) were evaluated in rats after intracerebroventricular (i.c.v.) administration. Neither CCK-8-SE nor CCK-8-NS induced any sign of catalepsy. When haloperidol, in a dose of 1.0 mg/kg (i.p.), and either CCK-8-SE or CCK-8-NS, in doses of 8, 80 or 800 pmol (i.c.v.), were applied at the same time, the peptides significantly decreased the total duration of catalepsy, the 80 pmol dose being the most effective. For the inhibition of catalepsy CCK-8-NS was the more active as it decreased catalepsy scores even 120 min after administration. Both peptides showed only transient effects on the fully developed catalepsy induced by haloperidol.
Asunto(s)
Catalepsia/inducido químicamente , Haloperidol/farmacología , Sincalida/farmacología , Animales , Antipsicóticos/farmacología , Humanos , Inyecciones Intraventriculares , Masculino , Ratas , Factores de TiempoRESUMEN
Various fragments of beta-lipotropin were micro-injected into the nucleus accumbens of free-moving rats and the effects on one-trial passive avoidance behaviour were studied. The following peptides were used: beta-endorphin (beta-LPH61-91), met-enkephalin (beta-LPH61-65), des-tyrosine-gamma-endorphin (DT gamma E, beta-LPH62-77), des-enkephalin-gamma-endorphin (DE gamma E, beta-LPH66-77), des-tyrosine-alpha-endorphin (DT alpha E, beta-LPH 62-76) and beta-LPH47-53(ACTH4-10). The gamma-type endorphins (DT gamma E and DE gamma E) were the only peptides which significantly attenuated passive avoidance behaviour when given in a 20 pg dose 1 hr before the 24-hr retention test. All the other peptides were ineffective. Microinjection of DT gamma E into the dentate gyrus of the dorsal hippocampus, on the other hand, was without effect on passive avoidance. The accumbens nucleus, therefore, is a preferential highly sensitive brain site for gamma-type endorphins. The attenuation of passive avoidance behaviour following systemic administration of these peptides might be the result of an interaction with this mesolimbic structure.
Asunto(s)
Reacción de Prevención/efectos de los fármacos , Conducta Animal/efectos de los fármacos , Endorfinas/farmacología , Núcleo Accumbens/fisiología , Núcleos Septales/fisiología , Animales , Relación Dosis-Respuesta a Droga , Endorfinas/administración & dosificación , Encefalinas/administración & dosificación , Encefalinas/farmacología , Inyecciones Intraventriculares , Masculino , Ratas , Ratas Endogámicas/fisiologíaRESUMEN
The anticonvulsive activity of cholecystokinin octapeptide sulphate ester (CCK-8-SE), non-sulphated cholecystokinin octapeptide (CCK-8-NS) and three different N- and C-terminal fragments were investigated against seizures induced by picrotoxin and electroshock in rats after intracerebroventricular administration. Doses of 0.8 and 80 pmol of CCK-8-SE and CCK-8-NS significantly enhanced the latency of seizures induced by picrotoxin and shortened the duration of the clonic phase of the seizures induced by electroshock. Only CCK-8-SE shortened the recovery time and only 0.8 pmol of CCK-8-SE could shorten the duration of the tonic phase of convulsions induced by electroshock. Doses of the octapeptides of 8000 pmol were ineffective, with the exception of CCK-8-NS in the picrotoxin test. Of the fragments tested, the C-terminal tetrapeptide, CCK-5-8, enhanced the latency of seizures induced by picrotoxin in a dose of 0.8 pmol, and had a dose-dependent biphasic effect on the duration of the clonic phase of seizures induced by electroshock. Intracerebroventricular administration of diazepam enhanced only the latency of tremor and clonic seizures induced with picrotoxin in a dose of 40 nmol. Twelve nmole of diazepam shortened the clonic phase of convulsions induced by electroshock. The peptides tested were much more active than diazepam, and their effective doses were comparable to the amounts of cholecystokinin octapeptide found in brain structures.
Asunto(s)
Anticonvulsivantes , Picrotoxina/toxicidad , Convulsiones/prevención & control , Sincalida/farmacología , Animales , Diazepam/farmacología , Electrochoque , Inyecciones Intraventriculares , Masculino , Fragmentos de Péptidos/farmacología , RatasRESUMEN
Cocaine is a widely used drug of abuse. One of the characteristic effects of this stimulant drug in the CNS of mice is the induction of motor hyperactivity. It was demonstrated that cocaine-induced motor hyperactivity could be blocked by pimozide, a dopamine receptor blocker, suggesting that dopamine was involved in cocaine-induced hyperactivity. Oxytocin, a neurohypophyseal neuropeptide, also partially antagonized cocaine-induced motor hyperactivity. Moreover, oxytocin antagonized the increased utilization of dopamine, elicited by cocaine in the nucleus accumbens. The data suggest that oxytocin may influence the behavioural effects of cocaine by affecting dopaminergic neurotransmission in some regions of the brain.
Asunto(s)
Cocaína/farmacología , Dopamina/fisiología , Actividad Motora/efectos de los fármacos , Oxitocina/farmacología , Animales , Relación Dosis-Respuesta a Droga , Masculino , Metiltirosinas/farmacología , Ratones , Ratones Endogámicos , Transmisión Sináptica/efectos de los fármacos , alfa-MetiltirosinaRESUMEN
Male rats with hyperprolactinaemia, induced by adenohypophyseal homografts under the kidney capsule, were injected with haloperidol for 3 days and then subjected to treatment with morphine, administered twice in a day at increasing doses for 12 days. At the first treatment, morphine induced an antinociceptive effect that was more prolonged in homografted rats than in sham-operated controls. The pretreatment with haloperidol did not change the prolongation of morphine-induced antinociception in homografted rats. After 12 days of treatment with morphine, all animals were tested for the development of tolerance to the antinociceptive effect of morphine. Pituitary homografts resulted in an inhibition of the development of tolerance, while this effect was absent in homografted rats pretreated with haloperidol. At the end of the treatment with morphine, the naloxone-precipitated abstinence syndrome was studied. Homografted rats shown an attenuation of the withdrawal syndrome and pretreatment with haloperidol did not change this response. These results suggest an involvement of dopaminergic transmission in prolactin-induced changes in the development of tolerance to morphine, but not in the antinociceptive effect following an acute injection of morphine and in naloxone-precipitated withdrawal syndrome of the rat.
Asunto(s)
Haloperidol/farmacología , Morfina/farmacología , Nociceptores/efectos de los fármacos , Prolactina/sangre , Síndrome de Abstinencia a Sustancias/fisiopatología , Animales , Tolerancia a Medicamentos , Masculino , Naloxona/farmacología , Adenohipófisis/trasplante , Ratas , Ratas Endogámicas , Tiempo de Reacción/efectos de los fármacosRESUMEN
The effects of centrally administered pituitary adenylate cyclase-activating polypeptide (PACAP-38) on body temperature were investigated in rats. Intracerebroventricular (i.c.v.) administration of PACAP-38 in doses of 500 and 1000 ng induced a dose-related elevation in colon temperature 2, 3, 4, 5 and 6 h after injection. The i.c.v. pretreatment of the animals with different dilutions of PACAP-38 antiserum prevented the development of hyperthermia in PACAP-38-treated animals, whereas PACAP-38 antiserum alone did not modify the colon temperature. An intramuscular injection of noraminophenazone (a cyclooxygenase inhibitor) abolished the PACAP-38-induced hyperthermia. Our data indicate that PACAP may induce hyperthermia via the central nervous system, and this hyperthermic effect may be mediated via a cyclooxygenase-involved pathway.
Asunto(s)
Fiebre/inducido químicamente , Neuropéptidos/farmacología , Aminopirina/farmacología , Animales , Temperatura Corporal/efectos de los fármacos , Colon/efectos de los fármacos , Colon/fisiología , Inhibidores de la Ciclooxigenasa/farmacología , Relación Dosis-Respuesta a Droga , Fiebre/fisiopatología , Inyecciones Intraventriculares , Masculino , Neuropéptidos/administración & dosificación , Neuropéptidos/antagonistas & inhibidores , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa , Ratas , Ratas WistarRESUMEN
The effects of oxytocin (OXT) and of dipeptides derived from the C-terminal portion of oxytocin (Z-prolyl-leucine and Z-prolyl-D-leucine) on the development of acute and chronic tolerance to, and dependence on morphine were tested in the mouse. Oxytocin and the dipeptides attenuated the development of acute and chronic tolerance to the antinociceptive effect of morphine and delayed the onset of the naloxone-precipitated withdrawal syndrome. Both oxytocin and Z-prolyl-D-leucine affected drug-induced behavioural responses related to dopamine (DA) in the brain. Thus, oxytocin potentiated the hypermotility induced by a large dose of apomorphine and decreased the supersensitivity of the DA receptors. Small doses of Z-prolyl-D-leucine inhibited the hypomotility elicited by a small dose of apomorphine and potentiated the hyperactivity induced by amphetamine. The data indicate that both oxytocin and Z-prolyl-D-leucine affect tolerance to and dependence on morphine. While oxytocin interacts mainly with postsynaptic DA-ergic neuronal elements, the dipeptide primarily affects DA-ergic neurotransmission at the presynaptic level.
Asunto(s)
Encéfalo/efectos de los fármacos , Dipéptidos/farmacología , Dopamina/fisiología , Morfina/farmacología , Oxitocina/farmacología , Transmisión Sináptica/efectos de los fármacos , Animales , Interacciones Farmacológicas , Tolerancia a Medicamentos , Humanos , Masculino , Ratones , Dependencia de Morfina/tratamiento farmacológicoRESUMEN
beta-(Tyr9)melanotropin-(9-18), which itself has no analgesic action, as measured by the tail-flick and hot-plate methods, decreased morphine-induced analgesia following intracerebroventricular injection. H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH heptapeptide, which has weak CRF-like activity, had no action on analgesia and was not able to modify morphine-induced analgesia. Compared with ACTH1-24, which in a subcutaneous dose of 100 micrograms/rat decreased morphine-induced analgesia, the same dose of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH was ineffective.
Asunto(s)
Analgesia , Hormonas Estimuladoras de los Melanocitos/farmacología , Morfina/antagonistas & inhibidores , Oligopéptidos/farmacología , Fragmentos de Péptidos/farmacología , Hormona Adrenocorticotrópica/farmacología , Animales , Inyecciones Intraventriculares , Inyecciones Subcutáneas , Masculino , Morfina/farmacología , RatasRESUMEN
Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice. Experiments with N- and C-terminal fragments revealed that the C-terminal tetrapeptide (CCK-5-8) was the active centre of the CCK octapeptide molecule. The analogues CCK-8-SE and CCK-8-NS (dose range 0.2-6.4 mumol/kg) and caerulein dose range 0.1-0.8 mumol/kg) showed bell-shaped dose-effect curves, with the greatest maximum inhibition for CCK-8-NS. The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced seizures and mortality. The maximum effect of the peptides tested was less than that of diazepam. Experiments with analogues and derivatives of CCK-5-8 demonstrated that the effectiveness of the beta-alanyl derivatives of CCK-5-8 were enhanced and that they were equipotent with CCK-8-SE. Of the CCK-2-8 analogues, Ser(SO3H)7-Ac-CCK-2-8-SE and Thr(SO3H)7-Ac-CCK-2-8-SE and Hyp(SO3H)-Ac-CCK-2-8-SE were slightly more active than CCK-8-SE.
Asunto(s)
Colecistoquinina/análogos & derivados , Colecistoquinina/farmacología , Picrotoxina/antagonistas & inhibidores , Convulsiones/inducido químicamente , Animales , Relación Dosis-Respuesta a Droga , Masculino , Ratones , Fragmentos de Péptidos/farmacología , Sincalida/farmacología , Relación Estructura-ActividadRESUMEN
Behavioural adaptation to and the effects of the neurohypophyseal peptide, oxytocin, on repeated treatment with cocaine were investigated in rats. The content of immunoreactive oxytocin in the plasma, hypothalamus and different limbic structures in the brain were also studied after treatment with cocaine, identical to that used in the behavioural experiment. Repeated administration of cocaine (7.5 mg/kg, s.c.) produced a behavioural tolerance to the stereotyped sniffing-inducing effect of the challenge doses (1.875, 3.75 and 7.5 mg/kg, s.c.) of cocaine on the fifth day, which was demonstrated by parallel shifting of the dose-response and time-effect curves of the test doses of cocaine. The development of tolerance was inhibited by pretreatment with oxytocin (0.05 micrograms, (s.c.), administered before each daily injection of cocaine. A smaller dose of oxytocin (0.005 micrograms, s.c.) had no effect in this model. A decreased amount of immunoreactive oxytocin was detected in the plasma, in the hypothalamus and in the hippocampus, after repeated treatment with cocaine. Replacement of oxytocin by local injection (100 pg) into the ventral hippocampus, before each daily administration of cocaine, prevented the development of tolerance to cocaine. These results suggest that endogenous oxytocin, localized in limbic-forebrain areas, may have an important regulatory role in the development of behavioural changes induced by the repeated administration of cocaine.
Asunto(s)
Encéfalo/metabolismo , Cocaína/farmacología , Oxitocina/farmacología , Conducta Estereotipada/efectos de los fármacos , Análisis de Varianza , Animales , Relación Dosis-Respuesta a Droga , Tolerancia a Medicamentos , Masculino , Oxitocina/administración & dosificación , Oxitocina/farmacocinética , Ratas , Ratas Wistar , Técnicas Estereotáxicas , Distribución TisularRESUMEN
Nine new analogues of acetyl-CCK-heptapeptide (Ac-Tyr(SO3H)2-Met3-Gly4-Trp5-Met6-Asp7-Phe8-NH2 ) were synthesized by solid-phase methodology. In a first series, the Asp7 residue was replaced by hydroxy amino acid sulfate esters. In another series, Gly4 was substituted by D-Ala, while Trp5 and Met6 were replaced by their D enantiomer. The introduction of the sulfate ester was performed with a new, mild, crystalline, and stable reagent, pyridinium acetyl sulfate. Each analogue that contained Tyr(SO3H)2 and a hydroxy amino acid sulfate ester [Ser(SO3H), Thr(SO3H), or Hyp(SO3H)] in position 7 proved to be more potent (1.9, 1.7, and 3.0 times, respectively) than CCK-8 in vitro (isolated gallbladder strips). While devoid of gastrin-like activity in vivo, these analogues had potent anticonvulsive activity. The analogues containing a D-amino acid residue were less potent than the parent compound in vitro. The D-Ala4 replacement, however, yielded a compound that was 40% as potent as CCK-8 in the in vitro test but showed prolonged duration of action on sphincter Oddi. While the 7-substituted Ac-CCK heptapeptides are among the most potent CCK analogues reported so far, the D-Ala4 replacement resulted, for the first time, in prolonged activity in vivo.
Asunto(s)
Colecistoquinina/análogos & derivados , Secuencia de Aminoácidos , Animales , Anticonvulsivantes/síntesis química , Perros , Vesícula Biliar/efectos de los fármacos , Ácido Gástrico/metabolismo , Ratones , Picrotoxina/farmacologíaRESUMEN
As the distribution of apelinergic neurons in the brain suggests an important role of apelin-13 in the regulation of neuroendocrine processes, in the present experiments the effects of this recently identified neuropeptide on the open-field activity, the hypothalamo-pituitary-adrenal (HPA) system and the body temperature were investigated. I.c.v. administration of apelin-13 (1-10 microg) to rats caused significant increases in square crossing, rearing, plasma corticosterone release and core temperature, whereas it did not influence the spontaneous motor activity during telemetric observation. To determine the mediation of the actions of apelin, a corticotropin-releasing hormone (CRH) antagonist, the nonselective dopamine antagonist haloperidol, the selective dopamine D1 receptor antagonist SCH-23390 and the nitric oxide synthase inhibitor Nomega-nitro-L-arginine-methyl ester (L-NAME) were administered to the rats. The apelin-evoked HPA activation was diminished by preadministration of the CRH antagonist, while the dopamine antagonist and L-NAME attenuated only the square crossing and rearing induced by apelin-13. To characterize the transmission of the thermoregulatory action of apelin, animals were pretreated either with L-NAME, the CRH antagonist or with the cyclooxygenase inhibitor noraminophenazone. L-NAME and the CRH antagonist did not cause significant inhibition of the apelin-evoked increase in core temperature, while the cyclooxygenase inhibitor, applied 30 min before peptide treatment, did not prove effective in preventing the apelin-evoked thermoregulatory response, whereas when it was administered 2 h after the peptide treatment, it transiently and significantly reduced the hyperthermic response. The present data suggest that apelin-13 plays an important role in the regulation of behavioral, endocrine and homeostatic responses in the CNS, and dopamine, nitric oxide and prostaglandins seem to take part in the mediation of its effects. Since the corticosterone response could be blocked by the CRH antagonist, it is likely to be mediated through the activation of the CRH neurons.
Asunto(s)
Conducta Animal/efectos de los fármacos , Regulación de la Temperatura Corporal/efectos de los fármacos , Proteínas Portadoras/farmacología , Sistemas Neurosecretores/efectos de los fármacos , Animales , Corticosterona/antagonistas & inhibidores , Corticosterona/sangre , Hormona Liberadora de Corticotropina/farmacología , Antagonistas de Dopamina/farmacología , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Interacciones Farmacológicas , Inhibidores Enzimáticos/farmacología , Conducta Exploratoria/efectos de los fármacos , Haloperidol/farmacología , Inyecciones Intraperitoneales/métodos , Péptidos y Proteínas de Señalización Intercelular , Masculino , Actividad Motora/efectos de los fármacos , NG-Nitroarginina Metil Éster/farmacología , Fragmentos de Péptidos/farmacología , Ratas , Ratas WistarRESUMEN
Previous publications have demonstrated a prominent central and corticotropin releasing hormone-mediated action of the endomorphins (EMs) on both open-field behaviour and the hypothalamo-pituitary-adrenal (HPA) axis. In the present experiments, the direct action of endomorphin-1 (EM1) on pituitary adrenocorticotropic hormone (ACTH) release, adrenal corticosterone secretion and the roles of nitric oxide (NO) and dopamine (DA) in the HPA and behavioural responses elicited by EM1 were investigated in mice. In vitro perifusion studies indicated that the action of EM1 on the HPA system appears to be confined to the hypothalamus, as EM1 did not influence the corticosterone secretion from adrenal slices and moderately attenuated the ACTH release from anterior pituitary slices. In in vivo experiments, NG-nitro-L-arginine (L-NNArg) pretreatment brought about a profound inhibition of both the endocrine and the behavioural responses. On the other hand, haloperidol completely abolished the increases in square crossing and rearing, without affecting corticosterone release. The direct action of EM1 on striatal DA release was therefore also investigated in an in vitro superfusion system. Although EM1 did not influence the basal release of tritiated DA, it significantly enhanced the transmitter release evoked by electric impulses and pretreatment with L-NNArg resulted in a considerable inhibition of the release elicited by EM1. In conclusion, our endocrine studies suggest an important role of NO in the mediation of the EM1-evoked corticosterone secretion. They also indicate that EM1 activates the HPA axis at a hypothalamic level and dopamine is not involved in this process. In contrast, the behavioural experiments reflect that the locomotor activation induced by EM1 is mediated by NO and dopamine, and the superfusion studies demonstrate that NO transmits the dopamine release enhancing effect of EM1.